Case Study: GLP-1 Cost Effectiveness and Coverage for Employer-Sponsored Health Plans
GLP-1 receptor agonists, or GLP-1 RAs, are changing the game for people living with Type 2 diabetes and obesity. These powerful medications, such as Ozempic, Trulicity, and Wegovy, not only help manage blood sugar levels but have also shown significant benefits in weight loss. However, due to their high cost and increasing demand, health plans and employers are facing challenges in providing coverage for these drugs.
Employer-sponsored health plans can expect a significant increase in claims expenses for GLP-1 drugs. For example, a company with 1,000 employees could spend around $900,000 in 2025. While GLP-1 drugs offer undeniable health benefits, including reduced rates of heart-related issues and a decrease in BMI, the financial strain on payers and the necessity of patient adherence to treatment plans underscore the complexity of incorporating these drugs into healthcare coverage.
Download our recent case study to gain a deeper understanding of GLP-1 receptor agonists and their impact on health plan coverage. It provides a detailed analysis of cost and utilization trends, and the steps employers can take to manage this growing expense while supporting their employees' health.
Download our case study today to unlock insights into GLP-1 and their impact on employer-sponsored health plans.
Related articles
As of mid-2025, the Representations and Warranties Insurance (“RWI”) market is experiencing notable shifts, influenced by fluctuating M&A activity and evolving underwriting practices. Market...
In the standard private equity platform stock acquisition, the Seller’s “occurrence” policies (e.g. workers’ compensation, general liability and auto liability) are portable and can continue...
When we think about mergers and acquisitions, the focus often lands on financials, valuations, and synergies. But behind the scenes, some of the most impactful work in an M&A transaction happens in...